Trade Genprex, Inc. - GNPX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0064 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.263 |
| Open | 0.2489 |
| 1-Year Change | -88.02% |
| Day's Range | 0.2489 - 0.2835 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 0.2808 | 0.0228 | 8.84% | 0.2580 | 0.2847 | 0.2441 |
| Apr 24, 2025 | 0.2630 | 0.0269 | 11.39% | 0.2361 | 0.2692 | 0.2330 |
| Apr 23, 2025 | 0.2325 | -0.0055 | -2.31% | 0.2380 | 0.2400 | 0.2260 |
| Apr 22, 2025 | 0.2198 | -0.0082 | -3.60% | 0.2280 | 0.2339 | 0.2127 |
| Apr 21, 2025 | 0.2189 | -0.0191 | -8.03% | 0.2380 | 0.2409 | 0.2127 |
| Apr 17, 2025 | 0.2380 | -0.0012 | -0.50% | 0.2392 | 0.2421 | 0.2266 |
| Apr 16, 2025 | 0.2488 | -0.0091 | -3.53% | 0.2579 | 0.2579 | 0.2376 |
| Apr 15, 2025 | 0.2459 | -0.0120 | -4.65% | 0.2579 | 0.2656 | 0.2459 |
| Apr 14, 2025 | 0.2623 | -0.0056 | -2.09% | 0.2679 | 0.2679 | 0.2289 |
| Apr 11, 2025 | 0.2645 | -0.0034 | -1.27% | 0.2679 | 0.2716 | 0.2588 |
| Apr 10, 2025 | 0.2635 | -0.0143 | -5.15% | 0.2778 | 0.2778 | 0.2455 |
| Apr 9, 2025 | 0.2649 | 0.0071 | 2.75% | 0.2578 | 0.2958 | 0.2469 |
| Apr 8, 2025 | 0.2518 | -0.0661 | -20.79% | 0.3179 | 0.3179 | 0.2402 |
| Apr 7, 2025 | 0.3077 | 0.0149 | 5.09% | 0.2928 | 0.3179 | 0.2589 |
| Apr 4, 2025 | 0.3334 | 0.0008 | 0.24% | 0.3326 | 0.3864 | 0.3188 |
| Apr 3, 2025 | 0.4309 | 0.1328 | 44.55% | 0.2981 | 0.4309 | 0.2855 |
| Apr 2, 2025 | 0.3299 | 0.0919 | 38.61% | 0.2380 | 0.3805 | 0.2380 |
| Apr 1, 2025 | 0.2198 | -0.0232 | -9.55% | 0.2430 | 0.2521 | 0.2198 |
| Mar 31, 2025 | 0.2432 | -0.0097 | -3.84% | 0.2529 | 0.2531 | 0.2222 |
| Mar 28, 2025 | 0.2699 | -0.0698 | -20.55% | 0.3397 | 0.3397 | 0.2475 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Genprex, Inc. Company profile
About Genprex Inc
Genprex, Inc. is a clinical-stage gene therapy company focused on developing treatments for cancer and diabetes. The Company's lead cancer drug candidate, REQORSA Immunogene therapy drug (also referred to as GPX-001), is being developed to treat non-small cell lung cancer (NSCLC). The active agent in REQORSA is a TUSC2 gene expressing plasmid that is encapsulated in a DOTAP cholesterol nanoparticle. TUSC2 is a tumor suppressor gene which has both tumor killing (via apoptosis) and immunomodulatory effects. The Company utilizes its ONCOPREX Nanoparticle Delivery System to deliver the TUSC2 gene expressing plasmid to cancer cells. Its diabetes gene therapy, also referred to as GPX-002, is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Genprex Inc revenues was not reported. Net loss increased 9% to $13.9M. Higher net loss reflects General and administrative increase of 13% to $8.8M (expense), Research and development increase of 3% to $5.1M (expense), Interest Income decrease of 76% to $4K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.39 to -$0.30.
| Industry: | Bio Therapeutic Drugs |
1601 Trinity Street, Bldg. B
Suite 3.322
AUSTIN
TEXAS 78712
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com